Institute of Chemical Biology and Fundamental Medicine

Institute of Chemical Biology and Fundamental Medicine of the Siberian Branch of the RAS, ICBFM SB RAS (Russian: Институт химической биологии и фундаментальной медицины СО РАН, ИХБФМ СО РАН) is a research institute in Novosibirsk, Russia. It was founded in 1984.

History

The Institute of Chemical Biology and Fundamental Medicine (formerly the Novosibirsk Institute of Bioorganic Chemistry) was founded on 1 April 1984.^[1]

Scientific activity

Creation of gene-targeted biological preparations, developments in the field of gene therapy, the study of physical and chemical processes of transmission and preservation of hereditary information.^[1]

Test system for detection of SARS-CoV-2 Omicron variant

At the end of 2021, the staff of the ICBFM SB RAS, together with scientists from Saint Petersburg, created a test system that simultaneously detects the presence of the genetic material of the coronavirus and determines whether it belongs to the omicron strain.^[1]

Method for inactivating the CRISPR/Cas9 genome editing system at a specific point in time

The CRISPR/Cas9 genome editing was discovered by molecular biologists Jennifer Doudna (United States) and Emmanuelle Charpentier (France), thanks to which they received the Nobel Prize.^[2]

Scientists at the ICBFM SB RAS have developed a method to inactivate the CRISPR/Cas9 genome editing system at a specific point in time.^[2]

In 2022, the institute received a patent for the invention – Modified guide RNA which has the ability to inactivate the CRISPR/Cas9 genome editing system, and method for obtaining it (Модифицированная направляющая РНК, обладающая способностью инактивировать систему редактирования генома CRISPR/Cas9, и способ ее получения).^[2]

References

54°51′01″N 83°06′16″E / 54.8504°N 83.1044°E / 54.8504; 83.1044